Head and neck cancer recurrence and mortality in nonselective cyclooxygenase inhibitor users

Archives of Otolaryngology - Head and Neck Surgery

Volumn 133, Issue 1, 2007, Pages 28-31

  Gillespie, M Boyd ^a,b   Moody, Marcus W ^a,b   Lee, Fu Shing ^a   Poole, Lynn J ^a   Hornig, Joshua D ^a   Lathers, Deanne ^a,b   Young, M Rita ^a,b   Day, Terry A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG USE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33846381328     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.133.1.28     Document Type: Article

References (17)

1. Blanke C. Role of COX-2 inhibitors in cancer therapy. Cancer Invest. 2004;22: 271-282.
2. Park SW, Lee SG, Song SH, et al. The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. Int J Cancer. 2003; 107:729-738.
3. Lin DT, Subbaramaiah K, Shah JP, et al. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002; 24:792-799.
4. Wang Z. The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des. 2005; 11:1771-1777.
5. Itoh S, Matsui K, Furuta I, Takano Y. Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor. Oral Oncol. 2003;39:829-835.
6. Terakado N, Shintani S, Yano J, et al. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 2004; 40:383-389.
7. Lang S, Zeidler R. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update. Int J Immunopathol Pharmacol. 2003; 16(2)(suppl):41-48.
8. Hashitani S, Urade M, Nishimura N, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol. 2003;23: 665-672.
9. 2 production. J Oral Pathol Med. 2001;30:41-47.
10. Gallo O, Masini E, Bianchi B, et al. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33:708-714.
11. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther. 2005;314:1-8.
12. Simon LS. The COX-2 inhibitors: a reasoned review of the data. Swiss Med Wkly. 2005;135:419-424.
13. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep. 2005;13:559-583.
14. Samoha S, Arber N. Cyclooxygenase-2 inhibition prevents colorectal cancer: from the bench to the bed side. Oncology. 2005;69(suppl 1):33-37.
15. Das UN. COX-2 inhibitors and metabolism of essential fatty acids. Med Sci Monit. 2005;11:RA233-RA237.
16. 2 synthesis. Clin Cancer Res. 2003;9:1885-1897.
17. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventative activities of celecoxib in oral carcinoma cells. Laryngoscope. 2002;112:839-843.